Projects per year
Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 19 Similar Profiles
Ovarian Neoplasms
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Drug Therapy
Medicine & Life Sciences
Natural Killer Cells
Medicine & Life Sciences
Endometrial Neoplasms
Medicine & Life Sciences
Hysterectomy
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Biomarkers
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2004 2022
Fallopian Tubes
Natural Killer Cells
Interleukin-2
Neoplasms
Fallopian Tubes
Carboplatin
Paclitaxel
Multicenter Studies
Placebos
Fallopian Tubes
Standard of Care
Platinum
Drug Therapy
olaparib
Metformin
Carboplatin
Paclitaxel
Placebos
Neoplasms
Fallopian Tubes
Platinum
Drug Therapy
Neoplasms
olaparib
Research Output 2000 2019
Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study
Lou, E., Vogel, R. I., Hoostal, S., Wong, P., Grad, A., Monu, M., Łukaszewski, T., Deshpande, J., Dickson, E. L., Klein, M. E., Linden, M. A., Subramanian, S., Teoh, D. G. & Geller, M. A., Jan 1 2019, In : Oncologist.Research output: Contribution to journal › Article
Circulating Neoplastic Cells
Platinum
MicroRNAs
Biomarkers
Prospective Studies
A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial
Vogel, R. I., Niendorf, K. B., Petzel, S., Lee, H., Teoh, D. G., Blaes, A. H., Argenta, P. A., Rivard, C., Winterhoff, B. J., Lee, H. Y. & Geller, M. A., Apr 1 2019, In : Gynecologic oncology. 153, 1, p. 100-107 8 p.Research output: Contribution to journal › Article
Mobile Applications
Telemedicine
Genetic Counseling
Ovarian Neoplasms
Randomized Controlled Trials
Corrigendum to “Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study” (Gynecologic Oncology (2018) 151(1) (18–23), (S0090825818310850) (10.1016/j.ygyno.2018.07.021))
Olawaiye, A. B., Java, J. J., Krivak, T. C., Friedlander, M., Mutch, D. G., Glaser, G., Geller, M. A., O'Malley, D. M., Wenham, R. M., Lee, R. B., Bodurka, D. C., Herzog, T. J. & Bookman, M. A., Jan 1 2019, In : Gynecologic oncology. 152, 1, 1 p.Research output: Contribution to journal › Comment/debate
Conflict of Interest
Adjuvant Chemotherapy
Ovarian Neoplasms
Financial Management
Consultants
3
Citations
(Scopus)
Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells
Uppendahl, L. D., Felices, M., Bendzick, L., Ryan, C., Kodal, B., Hinderlie, P., Boylan, K. L., Skubitz, A. P., Miller, J. S. & Geller, M. A., Apr 1 2019, In : Gynecologic oncology. 153, 1, p. 149-157 9 p.Research output: Contribution to journal › Article
Natural Killer Cells
Ovarian Neoplasms
Cytokines
Immunosuppressive Agents
Ascites
4
Citations
(Scopus)
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., DiSilvestro, P., Oza, A. M., Cristea, M., Berek, J. S., Chan, J. K., Rimel, B. J., Matei, D. E., Li, Y., Sun, K., Luptakova, K., Matulonis, U. A. & Monk, B. J., May 1 2019, In : The Lancet Oncology. 20, 5, p. 636-648 13 p.Research output: Contribution to journal › Article
Ovarian Neoplasms
Therapeutics
niraparib
Homologous Recombination
Platinum